摘要
目的临床观察高压氧联合英夫利昔单抗治疗溃疡性结肠炎的疗效,探索其作用机制。方法随机将50例溃疡性结肠炎患者分为治疗组26例和对照组24例,治疗组给予高压氧联合英夫利昔单抗治疗,对照组单用英夫利昔单抗治疗,共计治疗30周。结果治疗组综合疗效(92.3%)、英夫利昔单抗应答率(92.3%)及维持期谷浓度[(1.32±0.26)μg/ml]明显高于对照组[66.7%,66.7%,(0.74±0.22)μg/ml],差异有统计学意义(P<0.05或P<0.01);且治疗组可明显提升CD4^(+)、CD4^(+)/CD8^(+)水平,降低CD8^(+)及肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)和C反应蛋白(CRP)水平(P<0.05)。结论高压氧联合英夫利昔单抗治疗溃疡性结肠炎,可明显提高英夫利昔单抗的应答率,增强疗效;其机制可能是通过抑制T淋巴细胞的增殖,降低细胞因子的释放,达到治疗溃疡性结肠炎的目的。
Objective To observe the clinical efficacy of hyperbaric oxygen(HBO)combined with infliximab in the treatment of ulcerative colitis and explore its possible action mechanism.Methods A total of 50 patients with ulcerative colitis were randomly divided into treatment group(26 cases)and control group(24 cases).The treatment group was given HBO combined with infliximab,while the control group was given infliximab alone.Both groups were treated for 30 weeks.Results The comprehensive efficacy,infliximab response rate,and trough level of the maintenance period(from the 3rd to the 5th injection)in the treatment group were significantly higher than those of the control group with statistically significant differences,respectively[92.3%vs.66.7%,P<0.05;92.3%vs.66.7%,P<0.01;(1.32±0.26)μg/ml vs.(0.74±0.22)μg/ml,P<0.01];and the treatment group could significantly improve the levels of CD4^(+)and CD4^(+)/CD8^(+),reduce the levels of CD8^(+),TNF-α,IL-6,and CRP(P<0.05).Conclusion HBO combined with infliximab in the treatment of ulcerative colitis can significantly improve the response rate of infliximab and enhance the curative effect,which may be achieved by inhibiting the proliferation of T lymphocyte and reducing the release of inflammatory factors.
作者
乔翠霞
赵刚
张立泽
王丹丹
尤雯丽
万金娥
Qiao Cuixia;Zhao Gang;Zhang Lize;Wang Dandan;You Wenli;Wan Jin'e(Department of Anorectal Surgery,the Affiliated Hospital of Qingdao University,Qingdao 266003,China;Department of Hyperbaric Oxygen,the Affiliated Hospital of Qingdao University,Qingdao 266003,China)
出处
《中华航海医学与高气压医学杂志》
CAS
CSCD
2022年第5期636-639,643,共5页
Chinese Journal of Nautical Medicine and Hyperbaric Medicine
